Q-omics provides the consensus-scored PLA2G12B profile across patient tissues and cancer cell-line models. PLA2G12B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLA2G12B is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PLA2G12B RNA expression shows 11,299 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where PLA2G12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G12B survival associations across molecular data types. PLA2G12B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G12B RNA expression–survival associations across cancer types. High PLA2G12B expression shows unfavorable associations in CHOL, ACC, BLCA and LUSC, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLA2G12B RNA expression.
This table summarizes PLA2G12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G12B shows lower tumor expression in KIRP, LUSC, KICH and LUAD and higher tumor expression in THCA and KIRC. The THCA box plot shows higher PLA2G12B RNA expression in tumor versus normal tissue (log2 FC = +2.356, t-test p < 0.001).
This table shows molecular features associated with PLA2G12B in patient tissues and cancer cell lines. In patient samples, PLA2G12B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LIVER.
